Marshall Financial Group LLC Increases Holdings in Medpace Holdings, Inc. $MEDP

Marshall Financial Group LLC lifted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 4.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,070 shares of the company’s stock after acquiring an additional 135 shares during the quarter. Marshall Financial Group LLC’s holdings in Medpace were worth $979,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. GAMMA Investing LLC boosted its stake in shares of Medpace by 37.1% during the 1st quarter. GAMMA Investing LLC now owns 307 shares of the company’s stock worth $94,000 after acquiring an additional 83 shares in the last quarter. Zeno Equity Partners LLP boosted its stake in shares of Medpace by 2.6% during the 1st quarter. Zeno Equity Partners LLP now owns 62,304 shares of the company’s stock worth $18,983,000 after acquiring an additional 1,564 shares in the last quarter. United Services Automobile Association acquired a new position in shares of Medpace during the 1st quarter worth approximately $500,000. Hsbc Holdings PLC raised its position in shares of Medpace by 157.5% during the 1st quarter. Hsbc Holdings PLC now owns 4,364 shares of the company’s stock worth $1,296,000 after purchasing an additional 2,669 shares during the last quarter. Finally, Petrus Trust Company LTA acquired a new position in shares of Medpace during the 1st quarter worth approximately $203,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on MEDP shares. Barclays lifted their price objective on Medpace from $300.00 to $450.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 23rd. Rothschild Redb downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 3rd. Deutsche Bank Aktiengesellschaft boosted their price target on Medpace from $270.00 to $430.00 and gave the company a “hold” rating in a report on Wednesday, July 23rd. TD Cowen reiterated a “sell” rating and issued a $366.00 price target (up from $283.00) on shares of Medpace in a report on Wednesday, July 23rd. Finally, Mizuho boosted their price target on Medpace from $328.00 to $510.00 and gave the company an “outperform” rating in a report on Friday, July 25th. Two investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus target price of $422.27.

Insider Activity at Medpace

In other news, Director Cornelius P. Mccarthy III sold 1,662 shares of the firm’s stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $465.04, for a total transaction of $772,896.48. Following the transaction, the director owned 10,197 shares in the company, valued at approximately $4,742,012.88. This trade represents a 14.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Kevin M. Brady sold 12,000 shares of Medpace stock in a transaction on Thursday, July 24th. The stock was sold at an average price of $454.23, for a total transaction of $5,450,760.00. Following the completion of the transaction, the chief financial officer owned 6,000 shares in the company, valued at $2,725,380. This trade represents a 66.67% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 161,266 shares of company stock worth $74,111,427. 20.30% of the stock is currently owned by company insiders.

Medpace Stock Up 1.4%

MEDP opened at $497.83 on Thursday. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $506.55. The company’s 50-day moving average price is $439.91 and its 200 day moving average price is $352.60. The firm has a market cap of $13.98 billion, a price-to-earnings ratio of 37.01, a price-to-earnings-growth ratio of 3.09 and a beta of 1.44.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating analysts’ consensus estimates of $3.00 by $0.10. The business had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The business’s revenue for the quarter was up 14.2% on a year-over-year basis. During the same quarter last year, the business earned $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.